Cargando…
Advancing the Science of Vaccine Safety During the Coronavirus Disease 2019 (COVID-19) Pandemic and Beyond: Launching an International Network of Special Immunization Services( )
Within 2 years after the start of the coronavirus disease 2019 (COVID-19) pandemic, novel severe acute respiratory syndrome coronavirus 2 vaccines were developed, rigorously evaluated in large phase 3 trials, and administered to more than 5 billion individuals globally. However, adverse events of sp...
Autores principales: | Top, Karina A, Chen, Robert T, Levy, Ofer, Ozonoff, Al, Carleton, Bruce, Crawford, Nigel W, Creech, C Buddy, Kochhar, Sonali, Poland, Gregory A, Gutu, Kimberley, Cutland, Clare L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9376276/ https://www.ncbi.nlm.nih.gov/pubmed/35680552 http://dx.doi.org/10.1093/cid/ciac407 |
Ejemplares similares
-
Precision Vaccine Adjuvants for Older Adults: A Scoping Review( )
por: Nanishi, Etsuro, et al.
Publicado: (2022) -
Precision Vaccines: Lessons Learned From the Coronavirus Pandemic( )
por: Angelidou, Asimenia, et al.
Publicado: (2022) -
A Precision Adjuvant Approach to Enhance Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines Optimized for Immunologically Distinct Vulnerable Populations( )
por: Dowling, David J, et al.
Publicado: (2022) -
Perinatally Human Immunodeficiency Virus–Infected Adolescents and Young Adults Demonstrate Distinct BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine Immunogenicity( )
por: Morrocchi, Elena, et al.
Publicado: (2022) -
Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines: Perceptions and Attitudes From the Food and Drug Administration Public Commentary( )
por: Weitzman, Elissa R, et al.
Publicado: (2022)